AZTRNYSEPharmaceutical PreparationsFiscal year ends December 31

Azitra, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026

$0.07+0.00 (0.00%)

Close on Oct 19, 2026

Market cap: $1.38M
P/E (TTM): –
Dividend yield: –

Azitra, Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31
Revenue	0	0.01	0.69	0.28
Research & Development	4.84	4.72	3.64	6.10
General & Administrative	6.13	6.27	4.49	3.64
Operating Expenses	11	11	8.14	9.74
Operating Income	-11	-11	-7.45	-9.45
Interest Expense	0.01	0.01	0.17	0.25
Interest & Investment Income	0.07	0.12	0.00	0.00
Other Non-Operating Income	0.02	2.03	-3.82	-1.23
Asset Impairment Charges	0	0	0	–
Gain (Loss) on Sale of Assets	0.00	0.00	-0.04	-0.01
Pretax Income	-11	-8.96	-11	-11
Income Tax Expense	0.01	0.01	0.02	–
Net Income	-11	-8.97	-11	-11
Preferred Dividends	–	0	1.36	2.77
Net Income to Common	–	-8.97	-13	-13
EPS (Basic)(per share)	-2.25	-15.70	-366.53	-2,548.00
EPS (Diluted)(per share)	-2.25	-15.70	-366.53	-2,548.00
Shares Outstanding (Basic, Weighted)(shares)	4.87	0.57	0.03	0.01
Shares Outstanding (Diluted, Weighted)(shares)	4.87	0.57	0.03	0.01
EBITDA	-11	-11	-7.32	-9.33

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -230.7%

Financial strength

Current ratio: 4.86
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 439.5%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 0.19
Dividend yield: –